Pipeline
Our diverse pipeline includes innovative therapeutics and biobetters.
We focus on three key therapeutic areas: orphans, cancers and immune disorders.
ORPHAN
| Pipeline | Compound | Indication | Research | Pre-Clinical | Clinical Phase | ||
|---|---|---|---|---|---|---|---|
| I | II | III | |||||
| GX-H9 | Long-Acting hGH | Adult Growth Hormone Deficiency | 
|
|
|
|
|
| Pediatric Growth Hormone Deficiency |
|
|
|
|
|
||
| GX-G8 | GLP-2 | Short Bowel Syndrome |
|
|
|
|
|
| GX-30 | Thyroid-Stimulating Hormone (TSH) | A diagnostic agent for the follow-up of patients with thyroid cancer |
|
|
|
|
|
CANCER
| Pipeline | Compound | Indication | Research | Pre-Clinical | Clinical Phase | ||
|---|---|---|---|---|---|---|---|
| I | II | III | |||||
| GX-188E | DNA Therapeutic Vaccine | Cervical Intraepithelial Neoplasia 3 |
|
|
|
|
|
| Cervical Intraepithelial Neoplasia 2/3 |
|
|
|
|
|
||
| Cervical Cancer Trial with Checkpoint Inhibitor (CPI) |
|
|
|
|
|
||
| GX-I7 | IL-7 | Persistent HPVInfections |
|
|
|
|
|
| Lymphopenia |
|
|
|
|
|
||
| Solid Tumors |
|
|
|
|
|
||
| GX-G8 | GLP-2 | Chemotherapy-Induced Diarrhea |
|
|
|
|
|
IMMUNE DISORDER
| Pipeline | Compound | Indication | Research | Pre-Clinical | Clinical Phase | ||
|---|---|---|---|---|---|---|---|
| I | II | III | |||||
| GX-P2 | PD-L1 | Inflammatory Bowel Disease |
|
|
|
|
|
| Psoriasis |
|
|
|
|
|
||
BIOBETTER PROGRAM
| Pipeline | Compound | Indication | Research | Pre-Clinical | Clinical Phase | ||
|---|---|---|---|---|---|---|---|
| I | II | III | |||||
| GX-E2 | EPO | Anemia |
|
|
|
|
|
| GX-G3 | G-CSF | Neutropenia |
|
|
|
|
|
| GX-G6 | GLP-1 | Diabetes |
|
|
|
|
|
GX-02 and GX-051 overlapped with cancer pipelines to focus on emerging pipelines, which were shut down in March 2018.